Evidence of proatherogenic inflammation in polycystic ovary syndrome

Metabolism: Clinical and Experimental

Volumn 58, Issue 7, 2009, Pages 954-962

  González, Frank ^a   Rote, Neal S ^b   Minium, Judi ^b   Kirwan, John P ^c  

^a MAYO CLINIC   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; C REACTIVE PROTEIN; GELATINASE A; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LUTEINIZING HORMONE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRASTERONE SULFATE; TESTOSTERONE; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; ANDROGEN BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HOMEOSTASIS; HUMAN; HYPERANDROGENISM; HYPERGLYCEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LUTEINIZING HORMONE BLOOD LEVEL; MONONUCLEAR CELL; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ABSORPTIOMETRY, PHOTON; ADULT; ANDROGENS; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CHEMOKINE CCL2; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 2; NF-KAPPA B; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

EID: 66349113996     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.02.022     Document Type: Article

References (50)

1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18 (1997) 774-800
2. Knochenhauer E.S., Key T.J., Kahser-Miller M., Waggoner W., Boots L.R., and Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern Unites States: a prospective study. J Clin Endocrinol Metab 83 (1998) 3078-3082
3. The Rotterdam ESHRE/ASRM-Sponsored PCOS Conference Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
4. The Rotterdam ESHRE/ASRM-Sponsored PCOS Conference Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod 19 (2004) 41-47
5. Goodarzi M.O., and Korenman S.G. The importance of insulin resistance in polycystic ovary syndrome. Fertil Steril 77 (2002) 255-258
6. Burghen G.A., Givens J.R., and Kitabachi A.E. Correlation of hyperandrogenism with hyperinsulinemia in polycystic ovarian disease. J Clin Endocrinol Metab 50 (1980) 113-116
7. Nestler J.E., Jakubowicz D.J., de Vargas A.F., Brik C., Quintero N., and Medina F. Insulin stimulates testosterone biosynthesis by human theca cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 83 (1998) 2001-2005
8. Nigro J., Osman N., Dart A.M., and Little P.J. Insulin resistance and atherosclerosis. Endocr Rev 27 (2006) 242-259
9. Christian R.C., Dumesic D.A., Behrenbeck T., Oberg A.L., Sheedy II P.F., and Fitzpatrick L.A. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 2562-2568
10. Talbott E.O., Zborowski J.V., Rager J.R., Boudreaux M.Y., Edmundowicz D.A., and Guzick D.S. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 5454-5461
11. NIH, NHLBI. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults-the evidence report. Obesity Res 6 Suppl 2 (1998) 51S-209S
12. Colditz G.A., Willett W.C., Rotnitzky A., and Manson J.E. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 122 (1995) 481-486
13. Vgontzas A.N., Trakada G., Bixler E.O., Lin H.M., Pejovic S., Zoumakis E., et al. Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea. Metabolism 55 (2006) 1076-1082
14. Diamanti-Kandarakis E., Alexandraki K., Piperi C., Protogerou A., Katsikis T., Paterakis T., et al. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 36 (2006) 691-697
15. Hu W.H., Qiao J., Zhao S.Y., Zhang X.W., and Li M.Z. Monocyte chemoattractant protein-1 and its correlation with lipoprotein in polycystic ovary syndrome. Beijing Da Xue Xue Bao 38 (2006) 487-491
16. Boulman N., Leiba L.R., Shachar S., Linn R., Zinder O., and Blumenfeld Z. Increased C-reactive protean levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 89 (2004) 2160-2165
17. Lewandowski K.C., Komorowski J., O'Callaghan C.J., Tan B.K., Chen J., Prelevic G.M., et al. Increased circulating levels of matrix metalloproteinase-2 and -9 in women with polycystic ovary syndrome. J Clin Endocrinol Metab 91 (2006) 1173-1177
18. Orio Jr. F., Palomba S., Cascella T., Tauchmanova L., Nardo L.G., Di Biase S., et al. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?. Reprod Biomed Online 9 (2004) 505-510
19. Ibanez L., and de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 89 (2004) 1592-1597
20. Morin-Papunen L., Bautio K., Ruokonen A., and Hedberg P. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 4649-4654
21. Evans J.L., Goldfine I.D., Maddux B.A., and Grodsky G.M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23 (2002) 599-622
22. Mohanty P., Hamouda W., Garg R., Aljada A., Ghanim H., and Dandona P. Glucose challenge stimulates reactive oxygen species generation by leucocytes. J Clin Endocrinol Metab 85 (2000) 2970-2973
23. Barnes P.J., and Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336 (1997) 1066-1071
24. González F., Rote N.S., Minium J., and Kirwan J.P. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 91 (2006) 336-340
25. González F., Rote N.S., Minium J., and Kirwan J.P. Increased activation of nuclear factor κB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 91 (2006) 1508-1512
26. Romano M., Sironi M., Toniatti C., Polentarutti N., Fruscella P., Ghezzi P., et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6 (1997) 315-325
27. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
28. Heinrich P.C., Castell J.V., and Andus T. Interleukin-6 and the acute phase response. Biochem J 265 (1991) 621-636
29. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
30. Zwaka T.P., Hombach V., and Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103 (2001) 1194-1197
31. Vaughan D.E. PAI-1 and atherothrombosis. J Thromb Haemost 3 (1883) 1879-1883
32. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Res 85 (2005) 1-31
33. González F., Minium J., Rote N.S., and Kirwan J.P. Hyperglycemia alters tumor necrosis factor-α release from mononuclear cells in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 5336-5342
34. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
35. Modan M., Harris M.I., and Halkin H. Evaluation of WHO and NDDG criteria for impaired glucose tolerance. Results from two national samples. Diabetes 38 (1989) 1630-1635
36. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1885) 412-419
37. Kohrt W.M., Kirwan J.P., King D.S., Staten M.A., and Holloszy J.O. Insulin resistance of aging is related to abdominal obesity. Diabetes 42 (1993) 273-281
38. Taylor R.W., Keil D., Gold E.J., Williams S.M., and Goulding A. Body mass index, waist girth, and waist to hip ratio as indexes of total and regional adiposity in women: evaluation using receiver operating characteristic curves. Am J Clin Nutr 67 (1998) 44-49
39. Andrews N.C., and Faller D.V. A rapid micropreparation technique for extraction of DNA-binding proteins from limited numbers of mammalian cells. Nucleic Acids Res 19 (1991) 2499
40. González F., Minium J., Rote N.S., and Kirwan J.P. Altered tumor necrosis factor-α release from mononuclear cells of obese reproductive-age women during hyperglycemia. Metabolism 55 (2006) 271-277
41. Kirwan J.P., Krishnan R.K., Weaver J.A., Del Aguila L.F., and Evans W.J. Human aging is associated with altered TNF-α production during hyperglycemia and hyperinsulinemia. Am J Physiol Endocrinol Metab 281 (2001) E1137-E1143
42. Kirchengast S., and Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 16 (2001) 1255-1260
43. Ibanez L., and de Zegher F. Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. Hum Reprod 19 (2004) 1725-1727
44. Yildirim B., Sabir N., and Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil Steril 79 (2003) 1358-1364
45. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., and Ferrante Jr. A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112 (2003) 1796-1808
46. Fain J.N., Madan A.K., Hiler M.L., Cheema P., and Bahouth S.W. Comparison of the release of adiponectin by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinol 145 (2004) 2273-2282
47. González F., Rote N.S., Minium J., and Kirwan J.P. In vitro evidence that hyperglycemia stimulates tumor necrosis factor-α release in obese women with polycystic ovary syndrome. J Endocrinol 188 (2006) 521-529
48. McCrohon J.A., Jessup W., Handelsman D.J., and Celermajer D.S. Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular adhesion molecule-1. Circulation 99 (1999) 2317-2322
49. Zhu X.D., Bonet B., and Knopp R.H. 17β-Estradiol, progesterone and testosterone inversely modulate low-density lipoprotein oxidation and cytotoxicity in cultured placental trophoblast and macrophages. Am J Obstet Gynecol 177 (1997) 196-209
50. Adams M.R., Williams J.K., and Kaplan J.R. Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. Arterioscler Thromb Vasc Biol 15 (1995) 562-570